Overview

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Status:
RECRUITING
Trial end date:
2026-10-25
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the safety and tolerability of AMG 691 as single doses (healthy participants only) and multiple doses in healthy participants and participants with mild-to-moderate asthma.
Phase:
PHASE1
Details
Lead Sponsor:
Amgen